Variation in fibrinogen FGG and FGA genes and risk of stroke

Summary

Haplotypes of the fibrinogen gamma and alpha (FGG and FGA) genes are associated with the structure of the fibrin network and may therefore influence the risk of stroke. We investigated the relationship between common variation in these genes with ischemic and haemorrhagic stroke. The study was based on 6,275 participants of the prospective population-based Rotterdam Study who at baseline (1990 – 1993) were aged 55 years or over, free from stroke, and had successful assessment of at least one FGG or FGA single nucleotide polymorphisms (SNP). Common haplotypes were estimated using seven tagging SNPs across a 30 kb region containing the FGG and FGA genes. Follow-up for incident stroke was complete until January 1,2005. Associations between constructed haplotypes and risk of stroke were estimated with an age- and sex-adjusted logistic regression model. We observed 668 strokes, of which 393 were ischemic and 62 haemorrhagic, during a median follow-up time of 10.1 years. FGG+FGA haplotype 3 (H3) was associated with an increased risk of ischemic stroke (odds ratio [OR] 1.36, 95% confidence interval [CI] 1.09–1.69) and the risk estimate for hemorrhagic stroke was 0.71 (95% CI 0.46–1.09) compared to the most frequent H1. The FGG and FGA genes were not associated with stroke or its subtypes when analyzed separately. In conclusion, risk of ischemic stroke was higher in FGG+FGA H3 than in H1. The results suggested that an opposite association may exist for haemorrhagic stroke.

Keywords

Stroke - fibrinogen - haplotype

• References

• 1 Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Ann NY Acad Sci 2001; 936: 11-30.
• 2 Kant JA, Fornace AJJ, Saxe D. et al. Evolution and organization of the fibrinogen locus on chromosome 4: gene duplication accompanied by transposition and inversion. Proc Natl Acad Sci USA 1985; 82: 2344-2348.
• 3 Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K. et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505.
• 4 Maresca G, Di Blasio A, Marchioli R. et al. Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol 1999; 19: 1368-1377.
• 5 Danesh J, Lewington S, Thompson SG. et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. J Am Med Assoc 2005; 294: 1799-1809.
• 6 Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 2003; 89: 601-609.
• 7 Cooper AV, Standeven KF, Ariens RA. Fibrinogen gamma-chain splice variant gamma' alters fibrin formation and structure. Blood 2003; 102: 535-540.
• 8 Fatah K, Hamsten A, Blomback B. et al. Fibrin gel network characteristics and coronary heart disease: Relations to plasma fibrinogen concentration, acute phaes protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992; 68: 130-135.
• 9 Davey Smith G, Harbord R, Ebrahim S. Fibrinogen, C-reactive protein and coronary heart disease: does Mendelian randomization suggest the associations are non-causal?. QJM 2004 97: 163-166.
• 10 Dunn EJ, Ariens RA, de Lange M. et al. Genetics of fibrin clot structure: a twin study. Blood 2004; 103: 1735-1740.
• 11 Mills JD, Ariens RA, Mansfield MW. et al. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 2002; 106: 1938-1942.
• 12 Fowkes FG, Connor JM, Smith FB. et al. Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet 1992; 339: 693-696.
• 13 Green FR. Fibrinogen polymorphisms and atherothrombotic disease. Ann NY Acad Sci 2001; 936: 549-559.
• 14 Lim BC, Ariens RA, Carter AM. et al. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 2003; 361: 1424-1431.
• 15 Mannila MN, Eriksson P, Ericsson CG. et al. Epistatic and pleiotropic effects of polymorphisms in the fibrinogen and coagulation factor XIII genes on plasma fibrinogen concentration, fibrin gel structure and risk of myocardial infarction. Thromb Haemost 2006; 95: 420-427.
• 16 Mannila MN, Eriksson P, Lundman P. et al. Contribution of haplotypes across the fibrinogen gene cluster to variation in risk of myocardial infarction. Thromb Haemost 2005; 93: 570-577.
• 17 Carter AM, Catto AJ, Grant PJ. Association of the alpha-fibrinogen Thr312Ala polymorphism with post-stroke mortality in subjects with atrial fibrillation. Circulation 1999; 99: 2423-2426.
• 18 Carter AM, Catto AJ, Kohler HP. et al. alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism. Blood 2000; 96: 1177-1179.
• 19 Hofman A, Breteler MM, van Duijn CM. et al. The Rotterdam Study: Objectives and design update. Eur J Epidemiol 2007; 22: 819-829.
• 20 den Dunnen JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 2000; 15: 7-12.
• 21 Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow-up. Lancet 2002; 359: 1309-1310.
• 22 Epstein MP, Satten GA. Inference on haplotype effects in case-control studies using unphased genotype data. Am J Hum Genet 2003; 73: 1316-1329.
• 23 Lake SL, Lyon H, Tantisira K. et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 2003; 55: 56-65.
• 24 Schaid DJ, Rowland CM, Tines DE. et al. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70: 425-434.
• 25 Ajjan RA, Grant PJ. Role of clotting factors and fibrin structure in predisposition to atherothrombotic disease. Expert Rev Cardiovasc Ther 2005; 03: 1047-1059.
• 26 Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ. et al. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. Blood 2005; 106: 4176-4183.
• 27 Yu S, Sher B, Kudryk B. et al. Fibrinogen precursors. Order of assembly of fibrinogen chains. J Biol Chem 1984; 259: 10574-10581.
• 28 van 't Hooft FM, von Bahr SJ, Silveira A. et al. Two common, functional polymorphisms in the promoter region of the beta-fibrinogen gene contribute to regulation of plasma fibrinogen concentration. Arterioscler Thromb Vasc Biol 1999; 19: 3063-3070.
• 29 Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95: 1517-1532.
• 30 Martiskainen M, Pohjasvaara T, Mikkelsson J. et al. Fibrinogen gene promoter -455 A allele as a risk factor for lacunar stroke. Stroke 2003; 34: 886-891.
• 31 Kessler C, Spitzer C, Stauske D. et al. The apolipoprotein E and beta-fibrinogen G/A-455 gene polymorphisms are associated with ischemic stroke involving large-vessel disease. Arterioscler Thromb Vasc Biol 1997; 17: 2880-2884.
• 32 Uitte de Willige S, Doggen CJ, de Visser MC. et al. Haplotypes of the fibrinogen gamma gene do not affect the risk of myocardial infarction. J Thromb Haemost 2006; 04: 474-476.
• 33 Jood K, Danielson J, Ladenvall C. et al. Fibrinogen gene variation and ischemic stroke. J Thromb Haemost. 2008 in press.
• 34 Akey J, Jin L, Xiong M. Haplotypes vs single marker linkage disequilibrium tests: what do we gain?. Eur J Hum Genet 2001; 09: 291-300.
• 35 Uitte de Willige S, Rietveld IM, De Visser MC. et al. Polymorphism 10034C>T is located in a region regulating polyadenylation of FGG transcripts and influences the fibrinogen gamma'/gammaA mRNA ratio. J Thromb Haemost 2007; 05: 1243-1249.
• 36 Mosesson MW. Fibrinogen gamma chain functions. J Thromb Haemost 2003; 01: 231-238.
• 37 Cheung EY, Uitte de Willige S, Vos HL. et al. Fibrinogen gamma' in ischemic stroke: a case-control study. Stroke 2008; 39: 1033-1035.